Clear All
399 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9371 Vincristine Oncovin, Vincasar PFS 1 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1963 Jan 1, 2014 Jun 10, 2024 No Longer Used
J9375 Vincristine Oncovin, Vincasar PFS 2 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1963 Jan 1, 1988 Dec 31, 2010 No Longer Used
J9380* Vincristine Oncovin, Vincasar PFS 5 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1963 Jan 1, 1994 Dec 31, 2010 No Longer Used
J9390 Vinorelbine Navelbine 10 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1994 Jan 1, 1996 In Use
J9400 Ziv-aflibercept Zaltrap 1 mg Chemotherapy Recombinant Fusion Protein VEGF-IgG1 No 2012 Jan 1, 2014 In Use
J9600 Porfimer Photofrin 75 mg Chemotherapy Photosensitizing Agent Cytotoxin No 1995 Jan 1, 1998 In Use
J9999 Chemotherapy - non specific Not otherwise classified, antineoplastic drugs NA Chemotherapy No In Use
N/A Relacorilant Lifyorli 25mg, 100mg Chemotherapy Glucocorticoid Receptor (GR) Antagonist Yes 2026 In Use
N/A Dordaviprone MODEYSO 125mg Chemotherapy Protease Activator ClpP, dopamine D2 Yes 2025 In Use
N/A Ensartinib ENSACOVE 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Yes 2025 In Use
N/A Zidesamtinib Jideytro 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, ALK, TRK Yes 2026 In Use
N/A Zongertinib HERNEXEOS 60mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2025 In Use
N/A SEVABERTINIB Hyrnuo 10mg Chemotherapy Tyrosine Kinase Inhibitor HER2, EGFR Yes 2025 In Use
N/A Ziftomenib Komzifti 200mg Chemotherapy Enzyme Inhibitor KMT2A Yes 2025 In Use
N/A Avutometinib potassium and defactinib hydrochloride AVMAPKI FAKZYNJA CO-PACK 0.8mg and 200mg Chemotherapy MEK Inhibitor, Tyrosine Kinase Inhibitor MEK1/2, ERK1/2, KRAS Yes 2025 In Use
N/A Taletrectinib IBTROZI 272mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Yes 2025 In Use
NA Nintedanib Ofev 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Yes 2014 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
NA Trametinib Mekinist 0.5 mg Chemotherapy MEK Inhibitor BRAF Yes 2013 In Use
NA Palbociclib Ibrance 125 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
NA Ruxolitinib Jakafi 5 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Ribociclib Kisqali 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Osimertinib Tagrisso 80 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2015 In Use
NA Pazopanib Votrient 200 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT, Lck, FMS Yes 2009 In Use
NA Sunitinib malate Sutent 25 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.